Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Consent Decree On Ranbaxy Expands U.S. FDA Oversight To India

This article was originally published in PharmAsia News

Executive Summary

Ranbaxy set to lose 180-day exclusivity on three products, potentially five more as it begins process to meet new requirements.

You may also be interested in...



Ranbaxy Woes Continue With 30-plus Product Import Alert

FDA will lift a portion of its import alert for generic drugs made in two of Ranbaxy's facilities to allow the company to import antiviral ganciclovir to avoid a drug shortage

Patent Owners Would Get Better Shot At Quashing IPR Petitions Under USPTO Rule

Proposed rule would eliminate petitioner advantage when patent board is deciding whether to institute inter partes review of patent claims.

USPTO Allows Accelerated Path For COVID-19 Products Across Medical, Health Care Sectors

USPTO pilot program aims to examine applications for COVID-19 products subject to approval by FDA within 6 to 12 months. Prioritized examination is available solely for small entities and would save them $2,000.

Related Companies

UsernamePublicRestriction

Register

LL1132466

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel